Shiwen Guo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Shiwen Guo has a total of 66 co-authors. Here are the top co-authors by number of shared publications:
Zhou Qi
Department of Obstetrics and Gynecology, The Second Affiliated Xian Hospital of Xi'an Jiaotong University, Xi'an 710000, China; Department of Neurosurgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710000, China
3 shared publicationsDong Sheng Li
Hubei Key Laboratory of Embryonic Stem Cell Research, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei Province
2 shared publicationsJie Luo
Department of Neurosurgery, Affiliated Taihe Hospital of Xi'an Jiaotong University Health Science Center
2 shared publicationsRui Fu
Department of Neurosurgery, Affiliated Taihe Hospital of Xi'an Jiaotong University Health Science Center
2 shared publicationsShitao Zhang
Department of Neurosurgery, The First Affiliated Hospital of Xi’an Jiaotong University
2 shared publicationsYan Ding
Hubei Key Laboratory of Embryonic Stem Cell Research, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei Province
2 shared publications
Latest Publications
- Open Access
- 14 September 2026
- Published by Elsevier in Ecotoxicology and Environmental Safety
- Vol. 323, 120772
Single-cell and metabolomic profiling reveals brain cellular and metabolic disruptions in pregnant mice exposed to micro- and nanoplastics
- 14 September 2026
- Published by Elsevier in Ecotoxicology and Environmental Safety
- Vol. 323, 120772
Open AccessSingle-cell and metabolomic profiling reveals brain cellular and metabolic disruptions in pregnant mice exposed to micro- and nanoplastics
- Open Access
- 5 August 2026
- Published by Frontiers Media SA in Frontiers in Molecular Neuroscience
- Vol. 19, 1870499
Dynamic transcriptomic profiling of dorsal root ganglia reveals stage-specific mechanisms in diabetic neuropathic pain
Diabetic peripheral neuropathy (DPN) is the main clinical challenge faced by patients in the middle and advanced stages of diabetes. Due to the unclear cellular and molecular mechanisms, despite decades of in-depth research, its treatment methods are still limited. This study delineates the dynamic transcriptomic landscape of dorsal root ganglia (DRG) in streptozotocin (STZ)-induced diabetic male rats, integrating behavioral phenotyping and cross-model comparisons. We observed phenotypic heterogeneity, with only 60% of STZ-treated rats developing diabetic neuropathic pain (DNP group). In comparison, 37% remained pain-free (non-DNP group) despite comparable hyperglycemia and weight loss. RNA sequencing revealed stage-specific molecular signatures: early DNP (4 weeks post-STZ) involved PI3K-Akt/Ras signaling pathways, whereas late DNP (8 weeks) implicated several virus infection and neuroactive ligand-receptor pathways. Strikingly, 72% of differentially expressed genes (DEGs) at 8 weeks were unique to chronic DNP maintenance. Cross-model analysis demonstrated little overlap between DNP, bone cancer pain, and nerve injury models (<1% shared DEGs), with only Serpina3n universally upregulated. Functional annotations highlighted dysregulated extracellular matrix remodeling, immune receptor activity, and virus-related pathways unique to DNP progression. These findings reveal (1) intrinsic phenotypic variability in diabetic neuropathy progression, (2) temporally distinct pathogenic mechanisms governing DNP initiation versus persistence, and (3) a unique transcriptional fingerprint distinguishing DNP from other neuropathic pain etiologies. This work provides a roadmap for stage-specific therapeutic targeting and underscores the necessity of precision approaches in diabetic neuropathy management.
- 5 August 2026
- Published by Frontiers Media SA in Frontiers in Molecular Neuroscience
- Vol. 19, 1870499
Open AccessDynamic transcriptomic profiling of dorsal root ganglia reveals stage-specific mechanisms in diabetic neuropathic pain
Diabetic peripheral neuropathy (DPN) is the main clinical challenge faced by patients in the middle and advanced stages of diabetes. Due to the unclear cellular and molecular mechanisms, despite decades of in-depth research, its treatment methods are still limited. This study delineates the dynamic transcriptomic landscape of dorsal root ganglia (DRG) in streptozotocin (STZ)-induced diabetic male rats, integrating behavioral phenotyping and cross-model comparisons. We observed phenotypic heterogeneity, with only 60% of STZ-treated rats developing diabetic neuropathic pain (DNP group). In comparison, 37% remained pain-free (non-DNP group) despite comparable hyperglycemia and weight loss. RNA sequencing revealed stage-specific molecular signatures: early DNP (4 weeks post-STZ) involved PI3K-Akt/Ras signaling pathways, whereas late DNP (8 weeks) implicated several virus infection and neuroactive ligand-receptor pathways. Strikingly, 72% of differentially expressed genes (DEGs) at 8 weeks were unique to chronic DNP maintenance. Cross-model analysis demonstrated little overlap between DNP, bone cancer pain, and nerve injury models (<1% shared DEGs), with only Serpina3n universally upregulated. Functional annotations highlighted dysregulated extracellular matrix remodeling, immune receptor activity, and virus-related pathways unique to DNP progression. These findings reveal (1) intrinsic phenotypic variability in diabetic neuropathy progression, (2) temporally distinct pathogenic mechanisms governing DNP initiation versus persistence, and (3) a unique transcriptional fingerprint distinguishing DNP from other neuropathic pain etiologies. This work provides a roadmap for stage-specific therapeutic targeting and underscores the necessity of precision approaches in diabetic neuropathy management.
- Open Access
- 5 June 2024
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 15, 1384320
Predictive factors influencing outcome of early cranioplasty after decompressive craniectomy: a outcome prediction model study
Objective: The timing of cranioplasty (CP) has become a widely debated topic in research, there is currently no unified standard. To this end, we established a outcome prediction model to explore the factors influencing the outcome of early CP. Our aim is to provide theoretical and practical basis for whether patients with skull defects after decompressive craniectomy (DC) are suitable for early CP.Methods: A total of 90 patients with early CP after DC from January 2020 to December 2021 were retrospectively collected as the training group, and another 52 patients with early CP after DC from January 2022 to March 2023 were collected as the validation group. The Nomogram was established to explore the predictive factors that affect the outcome of early CP by Least absolute shrinkage analysis and selection operator (LASSO) regression and Logistic regression analysis. Receiver operating characteristic (ROC) curve was used to evaluate the discrimination of the prediction model. Calibration curve was used to evaluate the accuracy of data fitting, and decision curve analysis (DCA) diagram was used to evaluate the benefit of using the model.Results: Age, preoperative GCS, preoperative NIHSS, defect area, and interval time from DC to CP were the predictors of the risk prediction model of early CP in patients with skull defects. The area under ROC curve (AUC) of the training group was 0.924 (95%CI: 0.867–0.980), and the AUC of the validation group was 0.918 (95%CI, 0.842–0.993). Hosmer-Lemeshow fit test showed that the mean absolute error was small, and the fit degree was good. The probability threshold of decision risk curve was wide and had practical value.Conclusion: The prediction model that considers the age, preoperative GCS, preoperative NIHSS, defect area, and interval time from DC has good predictive ability.
- 5 June 2024
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 15, 1384320
Open AccessPredictive factors influencing outcome of early cranioplasty after decompressive craniectomy: a outcome prediction model study
Objective: The timing of cranioplasty (CP) has become a widely debated topic in research, there is currently no unified standard. To this end, we established a outcome prediction model to explore the factors influencing the outcome of early CP. Our aim is to provide theoretical and practical basis for whether patients with skull defects after decompressive craniectomy (DC) are suitable for early CP.Methods: A total of 90 patients with early CP after DC from January 2020 to December 2021 were retrospectively collected as the training group, and another 52 patients with early CP after DC from January 2022 to March 2023 were collected as the validation group. The Nomogram was established to explore the predictive factors that affect the outcome of early CP by Least absolute shrinkage analysis and selection operator (LASSO) regression and Logistic regression analysis. Receiver operating characteristic (ROC) curve was used to evaluate the discrimination of the prediction model. Calibration curve was used to evaluate the accuracy of data fitting, and decision curve analysis (DCA) diagram was used to evaluate the benefit of using the model.Results: Age, preoperative GCS, preoperative NIHSS, defect area, and interval time from DC to CP were the predictors of the risk prediction model of early CP in patients with skull defects. The area under ROC curve (AUC) of the training group was 0.924 (95%CI: 0.867–0.980), and the AUC of the validation group was 0.918 (95%CI, 0.842–0.993). Hosmer-Lemeshow fit test showed that the mean absolute error was small, and the fit degree was good. The probability threshold of decision risk curve was wide and had practical value.Conclusion: The prediction model that considers the age, preoperative GCS, preoperative NIHSS, defect area, and interval time from DC has good predictive ability.
- 24 January 2023
- Published by Springer Nature in Molecular Neurobiology
- Vol. 60 (5) , 2632-2643
Targeting of MALT1 May Improve Functional Recovery and Attenuate Microglia M1 Polarization-Mediated Neuroinflammation During Spinal Cord Injury
Mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) is involved in neural injury, neuroinflammation, microglia activation, and polarization, while its function in spinal cord injury (SCI) remains unclear. Thus, this study aimed to evaluate the role of MALT1 modification on SCI recovery and its underlying mechanism. SCI surgery or sham surgery was performed in Sprague–Dawley rats. Then, MALT1 knockdown or negative control lentivirus was injected into SCI rats. Subsequently, MALT1 expression, locomotor capability, neural injury, markers for microglia activation and polarization, inflammatory cytokine expressions, and nuclear factor (NF)-κB pathway were detected. SCI rats exhibited higher MALT1 expression, microglia activation and M1 polarization, neuroinflammation, and NF-κB pathway activation, while worse locomotor capacity compared to sham rats (all P < 0.05). In SCI rats, MALT1 knockdown alleviated Basso, Beattie, and Bresnahan score from 10 to 28 days and attenuated HE staining reflected neural injury (all P < 0.05). Besides, MALT1 knockdown declined the number of IBA1+ cells, IBA1+ iNOS+ cells, and IBA1+ CD86+ cells, while enhanced the number of IBA1+ Arg1+ cells and IBA1+ CD206+ cells in SCI rats (all P < 0.05). Meanwhile, MALT1 knockdown declined the expressions of IL-1β, IL-6, and TNF-α in SCI (all P < 0.05), but did not affect IL-10 expression (P > 0.05). Furthermore, MALT1 knockdown suppressed NF-κB pathway activation validated by immunofluorescence staining and western blot assays (all P < 0.05). MALT1 knockdown improves functional recovery, attenuates microglia activation, M1 polarization, and neuroinflammation via inhibiting NF-κB pathway in SCI.
- 24 January 2023
- Published by Springer Nature in Molecular Neurobiology
- Vol. 60 (5) , 2632-2643
Targeting of MALT1 May Improve Functional Recovery and Attenuate Microglia M1 Polarization-Mediated Neuroinflammation During Spinal Cord Injury
Mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) is involved in neural injury, neuroinflammation, microglia activation, and polarization, while its function in spinal cord injury (SCI) remains unclear. Thus, this study aimed to evaluate the role of MALT1 modification on SCI recovery and its underlying mechanism. SCI surgery or sham surgery was performed in Sprague–Dawley rats. Then, MALT1 knockdown or negative control lentivirus was injected into SCI rats. Subsequently, MALT1 expression, locomotor capability, neural injury, markers for microglia activation and polarization, inflammatory cytokine expressions, and nuclear factor (NF)-κB pathway were detected. SCI rats exhibited higher MALT1 expression, microglia activation and M1 polarization, neuroinflammation, and NF-κB pathway activation, while worse locomotor capacity compared to sham rats (all P < 0.05). In SCI rats, MALT1 knockdown alleviated Basso, Beattie, and Bresnahan score from 10 to 28 days and attenuated HE staining reflected neural injury (all P < 0.05). Besides, MALT1 knockdown declined the number of IBA1+ cells, IBA1+ iNOS+ cells, and IBA1+ CD86+ cells, while enhanced the number of IBA1+ Arg1+ cells and IBA1+ CD206+ cells in SCI rats (all P < 0.05). Meanwhile, MALT1 knockdown declined the expressions of IL-1β, IL-6, and TNF-α in SCI (all P < 0.05), but did not affect IL-10 expression (P > 0.05). Furthermore, MALT1 knockdown suppressed NF-κB pathway activation validated by immunofluorescence staining and western blot assays (all P < 0.05). MALT1 knockdown improves functional recovery, attenuates microglia activation, M1 polarization, and neuroinflammation via inhibiting NF-κB pathway in SCI.
- Open Access
- 13 February 2020
- Published by Spandidos Publications in International Journal of Molecular Medicine
- Vol. 45 (4) , 983-992
Tanshinone I induces apoptosis and protective autophagy in human glioblastoma cells via a reactive oxygen species‑dependent pathway
Glioma is the most common primary malignancy of the central nervous system and is associated with high mortality rates. Despite the available treatment options including surgery, radiotherapy and chemotherapy, the median patient survival rate is low. Therefore, the development of novel anticancer agents for the treatment of glioma is urgently required. Tanshinone I (TS I) is a tanshinone compound that is isolated from Danshen. Accumulating evidence indicates that TS I exhibits antiproliferative activity in a variety of cancer types. However, the role of TS I and its mechanism of action in human glioma remain to be elucidated. In the present study, the anticancer potential of TS I against human glioma U87 MG cells was investigated. The results indicated that TS I exerted a potential cytotoxic effect on human glioma U87 MG cells. TS I was found to induce cell proliferation, inhibition, cell cycle arrest, apoptosis and autophagy in U87 MG cells. Mechanistic experiments indicated that TS I activated endoplasmic reticulum (ER) stress and inhibited AKT signaling and apoptosis in human glioma U87 MG cells. Furthermore, the present study demonstrated that TS I induced protective autophagy in U87 MG cells. Additionally, ER stress and AKT signal‑mediated apoptosis and protective autophagy were found to be induced by TS I via intracellular reactive oxygen species accumulation. The results of the present study demonstrated that TS I may be a potential anticancer drug candidate that may be of value in the treatment of human glioma.
- 13 February 2020
- Published by Spandidos Publications in International Journal of Molecular Medicine
- Vol. 45 (4) , 983-992
Open AccessTanshinone I induces apoptosis and protective autophagy in human glioblastoma cells via a reactive oxygen species‑dependent pathway
Glioma is the most common primary malignancy of the central nervous system and is associated with high mortality rates. Despite the available treatment options including surgery, radiotherapy and chemotherapy, the median patient survival rate is low. Therefore, the development of novel anticancer agents for the treatment of glioma is urgently required. Tanshinone I (TS I) is a tanshinone compound that is isolated from Danshen. Accumulating evidence indicates that TS I exhibits antiproliferative activity in a variety of cancer types. However, the role of TS I and its mechanism of action in human glioma remain to be elucidated. In the present study, the anticancer potential of TS I against human glioma U87 MG cells was investigated. The results indicated that TS I exerted a potential cytotoxic effect on human glioma U87 MG cells. TS I was found to induce cell proliferation, inhibition, cell cycle arrest, apoptosis and autophagy in U87 MG cells. Mechanistic experiments indicated that TS I activated endoplasmic reticulum (ER) stress and inhibited AKT signaling and apoptosis in human glioma U87 MG cells. Furthermore, the present study demonstrated that TS I induced protective autophagy in U87 MG cells. Additionally, ER stress and AKT signal‑mediated apoptosis and protective autophagy were found to be induced by TS I via intracellular reactive oxygen species accumulation. The results of the present study demonstrated that TS I may be a potential anticancer drug candidate that may be of value in the treatment of human glioma.
- 4 September 2019
- Published by Elsevier in European Journal of Pharmacology
- Vol. 863, 172643
Circular RNA circ-PITX1 promotes the progression of glioblastoma by acting as a competing endogenous RNA to regulate miR-379–5p/MAP3K2 axis
- 4 September 2019
- Published by Elsevier in European Journal of Pharmacology
- Vol. 863, 172643
Circular RNA circ-PITX1 promotes the progression of glioblastoma by acting as a competing endogenous RNA to regulate miR-379–5p/MAP3K2 axis
- 28 December 2018
- Published by Wiley in Journal of Cellular Biochemistry
- Vol. 120 (6) , 10205-10214
Knockdown of SLC34A2 inhibits cell proliferation, metastasis, and elevates chemosensitivity in glioma
Solute carrier 34 A2 (SLC34A2) is a member of SLC34 family that is a group of phosphate transporters. SLC34A2 has been reported to play critical roles in tumorigenesis and progression. However, the researches about the biological roles of SLC34A2 in glioma have not yet been reported. In this study, we analyzed the expression patterns of SLC34A2 in clinical glioma tumor tissues and cell lines. The results demonstrated that SLC34A2 was generally overexpressed in both glioma tissues and cell lines. To further investigate the roles of SLC34A2 in glioma, lentivirus containing specific SLC34A2 short hairpin RNA (sh‐SLC34A2) was used to infect glioma cell lines U251 and U87 for the knockdown of SLC34A2. The following studies proved that SLC34A2 knockdown exhibited suppressive effects on cell proliferation and migration/invasion. SLC34A2 knockdown also inhibited epithelial‐mesenchymal transition (EMT) phenotype, as evidenced by the increased E‐cadherin expression, and the decreased N‐cadherin and fibronectin expressions. Besides, knockdown of SLC34A2 enhanced the temozolomide (TMZ) sensitivity of U251 and U87 cells. In vivo tumorigenicity assay demonstrated that SLC34A2 knockdown inhibited tumor growth. Moreover, SLC34A2 knockdown suppressed the activation of epidermal growth factor receptor (EGFR)/PI3K/AKT signaling pathway in U87 cells. GW2974 (EGFR inhibitor) increased SLC34A2 knockdown‐inhibited cell proliferation, migration/invasion, as well as enhanced SLC34A2 knockdown‐increased the TMZ sensitivity of glioma cells. These findings suggested that SLC34A2 might be a new potential therapeutic target for the therapy of glioma patients.
- 28 December 2018
- Published by Wiley in Journal of Cellular Biochemistry
- Vol. 120 (6) , 10205-10214
Knockdown of SLC34A2 inhibits cell proliferation, metastasis, and elevates chemosensitivity in glioma
Solute carrier 34 A2 (SLC34A2) is a member of SLC34 family that is a group of phosphate transporters. SLC34A2 has been reported to play critical roles in tumorigenesis and progression. However, the researches about the biological roles of SLC34A2 in glioma have not yet been reported. In this study, we analyzed the expression patterns of SLC34A2 in clinical glioma tumor tissues and cell lines. The results demonstrated that SLC34A2 was generally overexpressed in both glioma tissues and cell lines. To further investigate the roles of SLC34A2 in glioma, lentivirus containing specific SLC34A2 short hairpin RNA (sh‐SLC34A2) was used to infect glioma cell lines U251 and U87 for the knockdown of SLC34A2. The following studies proved that SLC34A2 knockdown exhibited suppressive effects on cell proliferation and migration/invasion. SLC34A2 knockdown also inhibited epithelial‐mesenchymal transition (EMT) phenotype, as evidenced by the increased E‐cadherin expression, and the decreased N‐cadherin and fibronectin expressions. Besides, knockdown of SLC34A2 enhanced the temozolomide (TMZ) sensitivity of U251 and U87 cells. In vivo tumorigenicity assay demonstrated that SLC34A2 knockdown inhibited tumor growth. Moreover, SLC34A2 knockdown suppressed the activation of epidermal growth factor receptor (EGFR)/PI3K/AKT signaling pathway in U87 cells. GW2974 (EGFR inhibitor) increased SLC34A2 knockdown‐inhibited cell proliferation, migration/invasion, as well as enhanced SLC34A2 knockdown‐increased the TMZ sensitivity of glioma cells. These findings suggested that SLC34A2 might be a new potential therapeutic target for the therapy of glioma patients.
- 13 June 2018
- Published by Wolters Kluwer Health in NeuroReport
- Vol. 29 (9) , 731-738
Ten-eleven translocation 1 regulates methylation of autophagy-related genes in human glioma
Ten-eleven translocation 1 catalyzes the conversion of 5-methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC), which plays an important role in epigenetics and is related to the malignant biological behavior of tumors. However, its regulatory role in glioma remains unclear. In this study, the levels of 5mC and 5hmC were detected using immunohistochemistry, dot-blot, hMeDIP-chip, and western blot in glioma tissues and normal brain tissues, whereas 5hmC differentially enriched genes were determined and further validated. The level of 5hmC in gliomas was decreased, whereas 5mC was increased. 5hmC highly enriched 10 functional protein-coding genes and 10 signaling pathways were identified using hMeGIP-chip in glioma tissues. Two autophagy-related genes, ATG13 and DNA damage-regulated autophagy modulator protein 1, with low enrichment of 5hmC in glioma tissues were verified in the promoter region, and hMeGIP-PCR further confirmed this result in U251 cells. Immunohistochemistry further confirmed that autophagy level in glioma tissues was lower than that of normal controls, and negatively correlated with WHO grade. This study indicates that ten-eleven translocation 1 may be involved in the development and progression of glioma through demethylation regulating a variety of cellular functions and signaling pathways, and autophagy is one of the regulatory mechanisms.
- 13 June 2018
- Published by Wolters Kluwer Health in NeuroReport
- Vol. 29 (9) , 731-738
Ten-eleven translocation 1 regulates methylation of autophagy-related genes in human glioma
Ten-eleven translocation 1 catalyzes the conversion of 5-methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC), which plays an important role in epigenetics and is related to the malignant biological behavior of tumors. However, its regulatory role in glioma remains unclear. In this study, the levels of 5mC and 5hmC were detected using immunohistochemistry, dot-blot, hMeDIP-chip, and western blot in glioma tissues and normal brain tissues, whereas 5hmC differentially enriched genes were determined and further validated. The level of 5hmC in gliomas was decreased, whereas 5mC was increased. 5hmC highly enriched 10 functional protein-coding genes and 10 signaling pathways were identified using hMeGIP-chip in glioma tissues. Two autophagy-related genes, ATG13 and DNA damage-regulated autophagy modulator protein 1, with low enrichment of 5hmC in glioma tissues were verified in the promoter region, and hMeGIP-PCR further confirmed this result in U251 cells. Immunohistochemistry further confirmed that autophagy level in glioma tissues was lower than that of normal controls, and negatively correlated with WHO grade. This study indicates that ten-eleven translocation 1 may be involved in the development and progression of glioma through demethylation regulating a variety of cellular functions and signaling pathways, and autophagy is one of the regulatory mechanisms.
- RetractedOpen Access
- 6 November 2017
- Published by Portland Press Ltd. in Bioscience Reports
- Vol. 37 (6)
TET1 exerts its tumour suppressor function by regulating autophagy in glioma cells
DNA methylation and demethylation play a critical role in the regulation of the molecular pathogenesis of gliomas. Tet methylcytosine dioxygenase 1 (TET1) catalyses the sequential oxidation of 5-methylcytosine (5mC) to 5-hydroxymethylcytosine, (5hmC) leading to eventual DNA demethylation. It has been reported that TET1 is a tumour suppressor in several cancers. However, whether TET1 plays a role in glioma development is largely unclear. Different glioma specimens and corresponding normal controls were collected to analyse the expression of TET1. At the same time, TET1 of glioma U251 cells was knocked down or overexpressed to observe its effect on glioma cell proliferation and invasion as well as autophagy level. Here, we reported that the expression of TET1 in glioma tissue was significantly lower than the corresponding non-tumour normal tissues, and the concentration of TET1 is negatively correlated with the glioma WHO classification. When TET1 gene in glioma U251 cells was knocked down by CRISPR/Caspase-9 system, the proliferation and invasive ability of U251 increased remarkably. But when TET1 was overexpressed in U251 cells, the proliferation and invasion were impaired. Following the down-expression of TET1, the level of autophagy in U251 cells decreased accordingly.However, when TET1 was overexpressed in U251 cells, the level of autophagy incraesed. Furthermore, bafilomycin A1 (Baf-A1) but not 3-methyladenine (3-MA) could decrease the autophagy level of TET1−/− U251 cells as the wild-type controls. It suggests that the tumour suppressor effect of TET1 seems to be mediated by regulating the level of autophagy, and the regulation of TET1 on autophagy is at an early stage.
- 6 November 2017
- Published by Portland Press Ltd. in Bioscience Reports
- Vol. 37 (6)
RetractedOpen AccessTET1 exerts its tumour suppressor function by regulating autophagy in glioma cells
DNA methylation and demethylation play a critical role in the regulation of the molecular pathogenesis of gliomas. Tet methylcytosine dioxygenase 1 (TET1) catalyses the sequential oxidation of 5-methylcytosine (5mC) to 5-hydroxymethylcytosine, (5hmC) leading to eventual DNA demethylation. It has been reported that TET1 is a tumour suppressor in several cancers. However, whether TET1 plays a role in glioma development is largely unclear. Different glioma specimens and corresponding normal controls were collected to analyse the expression of TET1. At the same time, TET1 of glioma U251 cells was knocked down or overexpressed to observe its effect on glioma cell proliferation and invasion as well as autophagy level. Here, we reported that the expression of TET1 in glioma tissue was significantly lower than the corresponding non-tumour normal tissues, and the concentration of TET1 is negatively correlated with the glioma WHO classification. When TET1 gene in glioma U251 cells was knocked down by CRISPR/Caspase-9 system, the proliferation and invasive ability of U251 increased remarkably. But when TET1 was overexpressed in U251 cells, the proliferation and invasion were impaired. Following the down-expression of TET1, the level of autophagy in U251 cells decreased accordingly.However, when TET1 was overexpressed in U251 cells, the level of autophagy incraesed. Furthermore, bafilomycin A1 (Baf-A1) but not 3-methyladenine (3-MA) could decrease the autophagy level of TET1−/− U251 cells as the wild-type controls. It suggests that the tumour suppressor effect of TET1 seems to be mediated by regulating the level of autophagy, and the regulation of TET1 on autophagy is at an early stage.